Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex Concentration in Dialysis Dependent Patients
NCT04556721Phase 1Withdrawn
- Start
- Sep 2021
- Primary completion
- Sep 2021
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Sugammadex in neuromuscular blockade (NMB). Primary endpoints: Plasma sugammadex concentration change from day of surgery to postoperative dialysis sessions and Plasma sugammadex-rocuronium complex concentration change from day of surgery to postoperative dialysis sessions. Planned start Sep 2021; status: withdrawn.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT04556721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04556721.